HSIC

Henry Schein, Inc.

77.65
USD
2.14%
77.65
USD
2.14%
70.25 92.68
52 weeks
52 weeks

Mkt Cap 10.85B

Shares Out 139.69M

Chat
Send me real-time posts from this site at my email

Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint

Integer Holdings Corporation ITGR recently announced its acquisition of Connemara Biomedical Holdings Teoranta, including its operating subsidiaries, Aran Biomedical and Proxy Biomedical (collectively known as Aran or Aran Biomedical). The buyout was completed for €120 million, with additional contingent consideration payable based on Aran Biomedical’s financial performance in 2022. It should be noted that Aran Biomedical is located in the medical device hub of Galway, Ireland. Thus, Integer Holdings’ latest acquisition expands its presence and proximity to customers in the region. The latest buyout is expected to enhance Integer Holdings’ ability to provide complete solutions for critical delivery and therapeutic devices in high-growth cardiovascular markets, such as structural heart and neurovascular, to name a few. This is likely to significantly solidify the company’s position in the global Medical space. Rationale Behind the Acquisition Aran Biomedical is a renowned provider of proprietary medical textiles, high-precision biomaterial coverings and coatings, as well as advanced metal and polymer braiding. In other words, it delivers development and manufacturing solutions for implantable medical devices. The buyout is likely to enhance Integer Holdings’ product offerings to a great extent, along with expanding its presence in high growth markets. Per Integer Holdings’ management, the addition of Aran Biomedical’s differentiated implant technology solutions to its own portfolio will likely enhance its ability to meet customers’ needs. It is also expected that Integer Holdings will be the customers’ partner of choice for creating the next generation of life-saving and life-enhancing medical devices. Industry Prospects Per a report by Research and Markets, the global biomaterials market was valued at $122.92 billion in 2020 and is anticipated to reach $725.88 billion by 2031 at a CAGR of approximately 17.9%. Factors like increasing demand for plastic surgery and wound-healing therapies, rise in prevalence of cardiovascular diseases and growing demand for implantable devices are likely to drive the market. Given the market potential, the latest buyout is likely to provide a significant boost to Integer Holdings’ business globally. Notable Development In February, Integer Holdings reported robust fourth-quarter 2021 results, wherein it recorded solid improvements in its top and bottom lines. The company also confirmed completing the acquisition of Oscor in December 2021. Oscor is a Florida-based private medical device company with significant manufacturing operations in the Dominican Republic. Shares of the company have lost 11.2% in the past year compared with the industry’s 3.4% fall. The S&P 500 has risen 6.9% in the same time frame. Zacks Rank & Key Picks Currently, Integer Holdings carries a Zacks Rank #3 (Hold). A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, McKesson Corporation MCK and Henry Schein, Inc. HSIC. AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare has gained 37.3% against the industry’s 57.6% fall over the past year. McKesson, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 11.9%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20.6%. McKesson has gained 69.2% compared with the industry’s 7.2% growth over the past year. Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2. Henry Schein has gained 30.1% compared with the industry’s 7.2% growth over the past year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue